Building on a $20 million funding round announced last month, Propeller Health said today that it landed an investment of an undisclosed amount from McKesson Ventures. The company is looking to expand its digital therapeutics business beyond devices that manage the treatment of chronic respiratory diseases. Propeller noted that it’s interested in exploring opportunities in […]
Precision NanoSystems raises $6m to fund nanomedicine manufacturing tech
Vancouver-based Precision NanoSystems said today that it closed a $6m Series B round, with investments from 5AM Ventures, Telegraph Hill Partners and Rising Tide Fund. The company is slated to use its newly-acquired funds to support the expansion of its services, including its nanomedicine manufacturing platform, NanoAssemblr. Precision NanoSystems’ technology is designed to enable the […]
Pavmed lands $10m from oversubscribed rights offering
Pavmed (NSDQ:PAVM) said today that it expects to reel in $10.4 million in gross proceeds from an oversubscribed rights offering that expired this week. The New York-based company received subscriptions exceeding the number of rights available under the offering, Pavmed said, adding that it anticipates the offering will close on June 12. According to the terms […]
Propeller raises $20m and prepares to extend reach beyond digital inhalers
Digital therapeutics company Propeller Health and drug-delivery device-maker Aptar Pharma are teaming up, yet again, to develop an array of connected drug-delivery devices. The pair has worked together in the past – in 2016, the companies launched the world’s first fully-integrated connected metered dose inhaler. Now, they hope to create a platform of digital therapeutics, […]
BioTime lands $1.9m grant to fund dry-AMD drug
BioTime Inc. (NYSE:BTX) said today that it won a $1.9 million grant from the Israel Innovation Authority to help support development of its dry-AMD drug, OpRegen. The company’s investigational therapy delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells in patients with macular degeneration. BioTime is testing its drug in a […]
RenovoRx raises $7m for drug-device pancreatic cancer therapy
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds […]
Cerus lands additional $15m in government funding
Cerus (NSDQ:CERS) landed a $15 million amendment to its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and Development Authority, bringing the total potential value of its deal to $201 million. The expanded agreement is designed to support additional clinical trials of the company’s Intercept blood transfusion technology. Cerus’ Phase III […]
Pavmed registers for $20m rights offering
Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock. The medical device company plans to offer the rights to purchase up to 9 million units at $2.25 apiece on May 21, valuing […]
Venture fund Foresite Capital raises largest-ever $668m fund
Life sciences venture firm Foresite Capital said today that it raised a record $668 million for its fourth fund, bringing its assets-under-management tally to $2 billion. San Francisco-based Foresite was founded in 2011 by former Theravance co-founder & CEO Dr. Jim Tananbaum. Investors in its fourth fund include “a significant representation of existing investors, including […]
EryDel raises $32m (€27m) for red blood cell drug delivery tech
Italian red blood cell drug delivery tech developer EryDel has raised $32 million (EU €26.5 million) in a new round of financing. The round was led by Sofinnova Partners and joined by existing shareholder Genextra SpA and Innogest SGR, according to a Sofinnova release. “We are thrilled to welcome Sofinnova Partners as our lead investor. […]
- 1
- 2
- 3
- …
- 20
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn